In a previous article, we explored one potential current opportunity for entrepreneurs interested in psychedelics and mycelium—producing non-psychoactive mushroom supplements. But are there any current commercial...more
5/31/2022
/ Clinical Trials ,
Food and Drug Administration (FDA) ,
Life Sciences ,
Pharmaceutical Industry ,
Popular ,
Proposed Legislation ,
Regulatory Standards ,
Religious Beliefs ,
Religious Exemption ,
Religious Freedom Restoration Act (RFRA) ,
Research and Development
Aside from a small number of companies the FDA has permitted to pursue the development of psilocybin therapies (e.g., Compass), the majority of psychedelic mushroom sales in the U.S. currently violate both state and federal...more
12/3/2021
/ Adverse Events ,
Advertising ,
Biologics ,
Controlled Substances Act ,
Dietary Supplements ,
Federal Food Drug and Cosmetic Act (FFDCA) ,
Food and Drug Administration (FDA) ,
GRAS ,
Labeling ,
Life Sciences ,
Marijuana ,
Popular ,
Reporting Requirements